News

Filter

1 to 9 of 17 results

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world

08-04-2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Additional indications in Japan for Diagnogreen and Sawacillin

22-02-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Ranbaxy back in black in fourth quarter as US sales soar

26-02-2010

India’s biggest pharmaceutical company Ranbaxy Laboratories has reported a profit of $106m for the…

Astellas PharmaDaiichi SankyoFlomaxGenericsGlaxoSmithKlineGlobalGSKMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSankyoTamsulosin HydrochlorideValacyclovir HydrochlorideValtrex

Foreign operations generating greater portion of sales at Japan’s Eisai; report

07-12-2009

Headquartered in Japan, Eisai operates in two main business areas: Pharmaceuticals, including ethical…

AciphexAriceptAstellas PharmaDaiichi SankyodonepezilEisaiFinancialKyowa HakkoMarkets & MarketingMGI PharmaPfizerPharmaceuticalRabeprazole SodiumSankyo

Japan's industry execs reiterate need to introduce drug price maintenance system

08-06-2009

Drug industry executives in Japan, including Toichi Takenaka, president of the Federation of Pharmaceutical…

Astellas PharmaDaiichi SankyoSankyo

1 to 9 of 17 results

Back to top